These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15963056)

  • 1. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.
    Melis D; Parenti G; Gatti R; Casa RD; Parini R; Riva E; Burlina AB; Dionisi Vici C; Di Rocco M; Furlan F; Torcoletti M; Papadia F; Donati A; Benigno V; Andria G
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):19-25. PubMed ID: 15963056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.
    Melis D; Cozzolino M; Minopoli G; Balivo F; Parini R; Rigoldi M; Paci S; Dionisi-Vici C; Burlina A; Andria G; Parenti G
    J Pediatr; 2015 Apr; 166(4):1079-82. PubMed ID: 25641239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
    Ficociello LH; Perkins BA; Silva KH; Finkelstein DM; Ignatowska-Switalska H; Gaciong Z; Cupples LA; Aschengrau A; Warram JH; Krolewski AS
    Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment.
    Venkat KK
    South Med J; 2004 Oct; 97(10):969-79. PubMed ID: 15558924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.
    Martens DH; Rake JP; Navis G; Fidler V; van Dael CM; Smit GP
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1741-6. PubMed ID: 19808227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal involvement in glycogen storage disease type 1: Practical issues].
    Ben Chehida A; Bensmaïl T; Ben Rehouma F; Ben Abdelaziz R; Azzouz H; Boudabbous H; Slim Abdelmoula M; Abdelhak S; Kaabachi N; Ben Turkia H; Tebib N
    Nephrol Ther; 2015 Jul; 11(4):240-5. PubMed ID: 25957470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria: clinical signficance and basis for therapy.
    Woo KT; Lau YK
    Singapore Med J; 2001 Aug; 42(8):385-9. PubMed ID: 11764058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to abandon microalbuminuria?
    Ruggenenti P; Remuzzi G
    Kidney Int; 2006 Oct; 70(7):1214-22. PubMed ID: 16871239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J; Abitbol C; Montané B; Zilleruelo G
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperfiltration and renal disease in glycogen storage disease, type I.
    Baker L; Dahlem S; Goldfarb S; Kern EF; Stanley CA; Egler J; Olshan JS; Heyman S
    Kidney Int; 1989 Jun; 35(6):1345-50. PubMed ID: 2671467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
    Remuzzi A; Malanchini B; Battaglia C; Bertani T; Remuzzi G
    Exp Nephrol; 1996; 4(1):19-25. PubMed ID: 8788596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
    van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
    Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.